Ian Irwin

TL;DR: It is proposed that this chemical selectively damages cells in the substantia nigra in patients who developed marked parkinsonism after using an illicit drug intravenously.

TL;DR: 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine appears effective in producing an animal model for Parkinson's disease in the squirrel monkey, and may be one of the more selective neurotoxins described to date.

TL;DR: Treatment of squirrel monkeys with pargyline prevents both clinical and neuropathological evidence of the neurotoxic effects of MPTP, and it is proposed that the conversion of MP TP to MPP+, possibly involving MAO, may be important for the neurot toxic effects to take place, and MPTP itself may not be the neurotoxicity agent.

TL;DR: It is reported that MPTP appears to be rapidly metabolized after systemic administration in toxic amounts, and 1-methyl-4-phenylpyridinium ion (MPP+) is identified as a probable major metabolite.

TL;DR: Findings suggest that similarities between the neuropathology of MPTP‐induced parkinsonism in the monkey and human Parkinson's disease are greater than first thought and increase the usefulness of the MPTP monkey model for research in Parkinson’s disease.